For people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

For Previously Untreated

Fixed-Duration Treatment With CALQUENCE + venetoclax*

A clinical study evaluated 2 groups of patients with previously untreated CLL. There were 291 patients who received CALQUENCE + venetoclax and 291 patients who received chemoimmunotherapy.^† The primary measurement of the study was progression-free survival (PFS), which is the amount of time patients were on treatment before their cancer started growing or spreading.

CALQUENCE + venetoclax reduced the risk of cancer growth or spread vs chemoimmunotherapy^†

At a median^‡ follow-up of 42.6 months, 69% (202 of 291 patients) receiving CALQUENCE + venetoclax lived without their CLL growing or spreading vs 67% (195 of 290 patients) receiving chemoimmunotherapy.* Individual results may vary.

*Designed to be completed as prescribed in 12.9 months (fourteen 28-day cycles) unless your doctor tells you to stop. Your doctor will monitor you while on treatment, and will stop treatment if your disease progresses or if you develop certain side effects.

^†Fludarabine + cyclophosphamide + rituximab (FCR) or bendamustine + rituximab (BR).

^‡Median is the middle number in a group of numbers arranged from lowest to highest.

Continuous Treatment With CALQUENCE^§

In a clinical study, 535 patients with previously untreated CLL received CALQUENCE alone (179 patients), CALQUENCE plus immunotherapy^¶ (179 patients), or chemoimmunotherapy^# (177 patients). The primary measurement of the study was progression-free survival (PFS), which is the amount of time patients were on treatment before their cancer started growing or spreading.

~2× more PATIENTS on CALQUENCE + immunotherapy^¶ had no cancer growth or spread vs chemoimmunotherapy^#

Percentage of patients whose CLL did not grow or spread after a median follow-up of 28.3 months

Individual results may vary.

0^%

(0 of 179 patients)

CALQUENCE + immunotherapy^¶

0^%

(0 of 179 patients)

CALQUENCE alone

0^%

(0 of 177 patients)

Chemoimmunotherapy^#

Long-term follow-up

Updated results were reported after a median^‡ follow-up of 6.2 years (74.5 months). Based on the limitations of this follow-up analysis after 6.2 years, results are descriptive only, and individual results may vary.

Percentage of people who had no cancer growth or spread at 6.2 years:

62% with CALQUENCE alone
78% with CALQUENCE + immunotherapy^¶
17% with chemoimmunotherapy^#

^§Take continuously and stop treatment if your disease progresses or if you develop certain side effects.

^¶CALQUENCE plus obinutuzumab.

^#Obinutuzumab plus chlorambucil.

For previously untreated patients
Continuous treatment with CALQUENCE was studied in a broad population including high-risk CLL patients with del(17p) or TP53 mutations.

Important Safety Information About CALQUENCE^® (acalabrutinib)

Before taking CALQUENCE, tell your healthcare provider about all of your medical conditions, including if you:

have had recent surgery or plan to have surgery. Your healthcare provider may stop CALQUENCE for any planned medical, surgical, or dental procedure.
have bleeding problems.
have or had heart rhythm problems.
have an infection.
have or had liver problems, including hepatitis B virus (HBV) infection.
are pregnant or plan to become pregnant. CALQUENCE may harm your unborn baby and cause problems during childbirth (dystocia).
Females who are able to become pregnant:
- Your healthcare provider may do a pregnancy test before you start treatment with CALQUENCE
- Use effective birth control (contraception) during treatment with CALQUENCE and for 1 week after the last dose of CALQUENCE
are breastfeeding or plan to breastfeed. It is not known if CALQUENCE passes into your breast milk. Do not breastfeed during treatment with CALQUENCE and for 2 weeks after your last dose of CALQUENCE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking CALQUENCE with certain other medications may affect how CALQUENCE works and can cause side effects. Especially tell your healthcare provider if you take a blood thinner medicine.

How should I take CALQUENCE?

Take CALQUENCE exactly as your healthcare provider tells you to take it.
Do not change your dose or stop taking CALQUENCE unless your healthcare provider tells you to.
Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking CALQUENCE if you develop certain side effects.
Take CALQUENCE 2 times a day (about 12 hours apart).
Take CALQUENCE with or without food.
Swallow CALQUENCE tablets whole with a glass of water. Do not chew, crush, dissolve, or cut tablets.
If you miss a dose of CALQUENCE, take it as soon as you remember. If it is more than 3 hours past your usual dosing time, skip the missed dose and take your next dose of CALQUENCE at your regularly scheduled time. Do not take an extra dose to make up for a missed dose.

What are the possible side effects of CALQUENCE?

CALQUENCE can cause serious side effects, including:

Serious infections have happened during treatment with CALQUENCE and may lead to death. Your healthcare provider may prescribe certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection, including fever, chills, or flu-like symptoms.
Bleeding problems (hemorrhage) have happened in people treated with CALQUENCE and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider right away if you have any signs or symptoms of bleeding, including blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or you cannot control, vomit blood or vomit that looks like coffee grounds, cough up blood or blood clots, dizziness, weakness, confusion, changes in your speech, headache that lasts a long time, or bruising or red or purple skin marks.
Decrease in blood cell counts. Decreased white blood cell counts, red blood cell counts, and platelet counts can be severe during treatment with CALQUENCE. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with CALQUENCE.
Second primary cancers. New cancers have happened in people during treatment with CALQUENCE, including cancers of the skin or other organs. Your healthcare provider will check you for skin cancers during treatment with CALQUENCE. Use sun protection when you are outside in sunlight.
Heart rhythm problems (cardiac arrhythmias) have happened in people treated with CALQUENCE, and can be serious or lead to death. Tell your healthcare provider right away if you have any of the following signs or symptoms: fast or irregular heartbeat, dizziness, feeling faint, chest discomfort, or shortness of breath.
Liver problems. Liver problems have happened in people treated with CALQUENCE, and can be severe or life-threatening, or lead to death. Tell your healthcare provider right away if you experience stomach pain or discomfort, urine of dark color or yellowing of your skin. Your healthcare provider will request tests to monitor your liver function during treatment with CALQUENCE.

The most common side effects of CALQUENCE include upper respiratory infection, diarrhea, headache, muscle and joint pain, decreased white blood cell counts, and decreased platelet counts.

These are not all the possible side effects of CALQUENCE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is CALQUENCE?

CALQUENCE is a prescription medicine used to treat adults with:

Mantle cell lymphoma (MCL) in combination with bendamustine and rituximab in people who have not had prior treatment for MCL and who cannot receive a type of stem cell transplant that uses their own blood stem cells (autologous hematopoietic stem cell transplantation [HSCT]).
Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

It is not known if CALQUENCE is safe and effective in children.

Please see full Prescribing Information, including Patient Information .

You may report side effects related to AstraZeneca
products.

Fixed-Duration Treatment With CALQUENCE + venetoclax*

Continuous Treatment With CALQUENCE§

~2× more PATIENTS on CALQUENCE + immunotherapy¶ had no cancer growth or spread vs chemoimmunotherapy#

Long-term follow-up

Important Safety Information About CALQUENCE® (acalabrutinib)

Continuous Treatment With CALQUENCE^§

~2× more PATIENTS on CALQUENCE + immunotherapy^¶ had no cancer growth or spread vs chemoimmunotherapy^#

Important Safety Information About CALQUENCE^® (acalabrutinib)